This widespread mislabeling has significant clinical consequences. Patients labeled as penicillin-allergic are often prescribed alternative antibiotics, which are associated with higher rates of treatment failure, adverse drug events, and the development of antibiotic-resistant bacteria.
Recognizing this as a major public health concern, the Centers for Disease Control and Prevention (CDC), American Academy of Allergy, Asthma & Immunology (AAAAI), Society for Healthcare Epidemiology of America (SHEA), and Infectious Diseases Society of America (ISDA) strongly advocate for the implementation of penicillin allergy delabeling protocols. These programs do not require an allergist and can be safely performed in most healthcare settings. A thorough allergy history, followed by an oral amoxicillin challenge, is often sufficient to rule out a true allergy.
There are not enough allergists available to perform penicillin allergy delabeling. Therefore, it is important that primary care providers and healthcare institutions be informed and take a proactive role in delabeling patients. Doing so improves antibiotic stewardship, enhances patient safety, and supports better health outcomes.
The on-demand webinars below are designed for healthcare providers in hospitals and primary care settings including physicians, advanced practitioners, pharmacists, and nurses as well as antibiotic stewardship specialists and infection preventionists.